Abstract
The endocannabinoid system comprises the cannabinoid receptors type 1 (CB1) and type 2 (CB2), their endogenous ligands (endocannabinoids) and the whole apparatus appointed of their synthesis and degradation. Recent studies investigated the possibility that drugs targeting the endocannabinoid system might be used to retard or block cancer growth. CB1, CB2 and metabolic enzymes of endocannabinoids, function in the context of lipid rafts, specialized membrane microdomains enriched in cholesterol, sphingolipids and glycosphingolipids which may be important in modulating signal transduction. Here, we analysed the role of lipid rafts/caveolae in the intracellular signaling and trafficking of cannabinoid receptor agonist in cancer cells. Perturbation of lipid rafts/caveolae may in fact represent a useful tool for the development of a novel therapy for endocannabinoids-related diseases, such as cancer. Also, we report the more recent developments of endocannabinoids in cancer drug discovery.
Keywords: Endocannabinoids, cancer, lipid rafts, Δ9-tetrahydrocannabinol, depolarization, capsaicin, 2-arachidonoyl-glycerylether
Mini-Reviews in Medicinal Chemistry
Title:Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids
Volume: 12 Issue: 11
Author(s): Claudia Grimaldi and Anna Capasso
Affiliation:
Keywords: Endocannabinoids, cancer, lipid rafts, Δ9-tetrahydrocannabinol, depolarization, capsaicin, 2-arachidonoyl-glycerylether
Abstract: The endocannabinoid system comprises the cannabinoid receptors type 1 (CB1) and type 2 (CB2), their endogenous ligands (endocannabinoids) and the whole apparatus appointed of their synthesis and degradation. Recent studies investigated the possibility that drugs targeting the endocannabinoid system might be used to retard or block cancer growth. CB1, CB2 and metabolic enzymes of endocannabinoids, function in the context of lipid rafts, specialized membrane microdomains enriched in cholesterol, sphingolipids and glycosphingolipids which may be important in modulating signal transduction. Here, we analysed the role of lipid rafts/caveolae in the intracellular signaling and trafficking of cannabinoid receptor agonist in cancer cells. Perturbation of lipid rafts/caveolae may in fact represent a useful tool for the development of a novel therapy for endocannabinoids-related diseases, such as cancer. Also, we report the more recent developments of endocannabinoids in cancer drug discovery.
Export Options
About this article
Cite this article as:
Grimaldi Claudia and Capasso Anna, Role of Lipid Rafts/Caveolae in the Anticancer Effect of Endocannabinoids, Mini-Reviews in Medicinal Chemistry 2012; 12 (11) . https://dx.doi.org/10.2174/138955712802762158
DOI https://dx.doi.org/10.2174/138955712802762158 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets From QTL to Candidate Gene: A Genetic Approach to Alcoholism Research
Current Drug Abuse Reviews Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review
Current Genomics Serum Testosterone and Cognitive Function in Ageing Male: Updating the Evidence
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Resveratrol and Cancer Treatment: Is Hormesis a Yet Unsolved Matter?
Current Pharmaceutical Design Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Natural Bioactives as Potential Therapeutic Modalities Against NeuroAIDS
Current Topics in Medicinal Chemistry Histone Deacetylase (HDAC) Inhibitors as Potential Drugs to Target Memory and Adult Hippocampal Neurogenesis
Current Psychopharmacology Emerging Role of JNK in Insulin Resistance
Current Diabetes Reviews Role of Acetylcholinesterase Inhibitors in the Metabolism of Amyloid Precursor Protein
Current Drug Targets - CNS & Neurological Disorders Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research An Overview of Targeting Legumain for Inhibiting Cancers
Current Pharmaceutical Design Towards Tyrosine Metabolism in Esophageal Squamous Cell Carcinoma
Combinatorial Chemistry & High Throughput Screening Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Current Pharmaceutical Design Control of β-Site Amyloid Precursor Protein-Cleaving Enzyme-1 Expression by Protein Kinase C-λ/ι and Nuclear Factor κ-B
Current Alzheimer Research Triterpenoid Saponins from Two Panax japonicus Varietals Used in Tujia Ethnomedicine
Current Traditional Medicine